DXCM CMS decision and 15-Day sensor rollout eyed to lift 2027 growth
DXCM says CMS review tied to type 2 non-insulin coverage, plus its 15-Day sensor and AI features, could support market expansion by mid-2027 and improve growth and margins.
Strong Connect study results and ongoing CMS review for type 2 non-insulin coverage could drive significant market expansion by mid-2027. Product innovation, including the 15-Day sensor and AI-driven features, supports growth and margin improvement, with global rollout and new pipeline launches on…